Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Mitchell Simons

Pain Medicine Cincinnati, OH Medical Doctor

NPI 1215003355 CMS profile 145347

4243 Hunt Rd, Cincinnati, OH 45242

Open in the dashboard

General payments

$5,449

508 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Mitchell Simons of Cincinnati, OH is reported in the CMS Open Payments database as having received $5,449 across 508 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $25 1
2021 General $765 45
2020 General $1,861 142
2019 General $2,798 320

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mitchell Simons
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Mitchell Simons were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Mitchell Simons Pain Medicine median Middle half National median
2019 $2,798 $498 $126–$1,682 $163
2020 $1,861 $284 $80–$910 $114
2021 $765 $399 $112–$1,219 $132
2022 $0 $455 $137–$1,484 $149
2023 $0 $484 $128–$1,495 $160
2024 $25 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boston Scientific Corporation $875 84 payments
  2. Pfizer Inc. $685 77 payments
  3. Amgen Inc. $674 27 payments
  4. Teva Pharmaceuticals USA, Inc. $479 63 payments
  5. Collegium Pharmaceutical, Inc. $433 27 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $415 44 payments
  7. ASSERTIO THERAPEUTICS, Inc. $319 64 payments
  8. Daiichi Sankyo Inc. $311 36 payments
  9. Biodelivery Sciences International, Inc. $273 19 payments
  10. Novartis Pharmaceuticals Corporation $146 11 payments
  11. Other $840 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,442 507 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2024
  1. AIMOVIG $820 38 payments
  2. SPECTRA WAVEWRITER $667 71 payments
  3. LYRICA $505 68 payments
  4. XTAMPZA $433 27 payments
  5. EMBEDA $295 41 payments
  6. Morphabond ER $289 34 payments
  7. AJOVY $282 28 payments
  8. FLECTOR PATCH $248 33 payments
  9. BELBUCA $214 14 payments
  10. Zipsor $207 46 payments
  11. Other $2,715 298 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

508 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record